- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03056495
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease (VostatAD01)
Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The MTD of Vorinostat in the treatment of Alzheimer's patients is to be determined by using an open, non-randomized, multicentric dose-finding study with adaptive design. This Clinical Trial will take place in 2 parts.
The first part will be performed as a dose escalation part in cohorts of three subjects. Possible dosages will be: one, two, three or four capsules (100 mg per capsule) once per day. The first cohort receives a dose of 100 mg per day. After the treatment, a Vorinostat-free follow-up phase will take place. For the following cohorts, dose increases, a repetition of the previous dose or a dose reduction are possible.
After the dose escalation with a determination of the MTD, a dosage confirmation is carried out with additional subjects. The subjects are given a dose of Vorinostat of MTD over 4 weeks followed by a Vorinostat-free follow-up phase.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sandra Kuhs, Dr. rer. nat.
- Phone Number: 0049-228-43302-846
- Email: sandra.kuhs@dzne.de
Study Locations
-
-
-
Bonn, Germany, 53127
- German Center for Neurodegenerative Diseases
-
Göttingen, Germany, 37075
- University Medical Center Göttingen, Department of Psychiatry and Psychotherapy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- written informed consent to participate in the study
- verified capacity to consent by a doctor not involved in the study
- mild Alzheimer's disease (NINCDS / ADRDA criteria and Mini-Mental State Examination (MMSE) 22-27)
- age (including) from 55 to 90 years
- subjects must be able to meet the requirements described in the study protocol
- outpatient living
- Informant lives with subject in the same household
- Rosen modified Hachinski ischemia score ≤4
- concerning only female patients: postmenopausal
- concerning only male patients: commitment to use a suitable contraceptive
- cerebral imaging study (CT or cMRI), which is consistent with a diagnosis of probable Alzheimer's disease (not older than 3 years)
Exclusion Criteria:
- other neurological and psychiatric diseases explaining cognitive deficits better than an AD diagnosis
- conspicuous MRI / CCT scan explaining the cognitive deficits better than an AD diagnosis
- severe physical, neurological or psychiatric disorders that interfere with the participation in the study
- history of malignant tumors except non- metastasizing basal cell carcinoma of the skin
- history of seizures
- dysphagia leading to the inability to swallow capsules
- untreated severe acute infections with clinical symptoms such as respiratory infections, pneumonia, bronchitis, acute diarrhea, influenza, untreated urinary tract infections
- in the family history, unexplained sudden cases of heart failure before the age of 50 years
- long QT syndrome in the family history
- evidence of QTc prolongation ≥480 ms at screening (Fridericia adjusted QT interval), of arrhythmias especially of severe uncontrolled ventricular arrhythmias or atrial fibrillation in ECG
- not sufficiently treated angina
- heart failure (NYHA III, IV)
- myocardial infarction
- known infection with HBV, HCV and / or HIV
- occurrence of venous thrombosis or embolism
- therapy with antidepressants begun in the last 12 weeks or dose modification of a pre-existing therapy with antidepressants
- antidiabetic treatment begun in the last 12 weeks or dose modification of pre-existing antidiabetic treatment
- long-term use of anti-inflammatory drugs except acetylsalicylic acid for cardiovascular prophylaxis
- current treatment or treatment within the past 12 weeks with HDAC inhibitors (eg valproate)
- taking medication that may increase the dose-dependent side effects myelosuppression or QTc interval prolongation.
These include, but are not limited to:
- Class Ia antiarrhythmic agents such as quinidine, procainamide, disopyramide
- Class III antiarrhythmic drugs such as amiodarone, sotalol, ibutilide
- Class Ic antiarrhythmics such as flecainide, propafenone
- penicillamine
- opioids such as methadone and pyrazolone derivatives such as metamizole and Propyphenazone
- doxorubicin, epirubicin
- macrolides and their analogues such as erythromycin, clarithromycin
- telithromycin
- oxazolidinones such as linezolid
- quinolones such as moxifloxacin, levofloxacin
- fluoxetine, maprotiline
- tricyclic and tetracyclic antidepressants
- chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone and clozapine
- antiemetics
- azole like ketoconazole, fluconazole, voriconazole
- aminocholine such as primaquine
- pentamidine such as quinine, chloroquine
- diaminopyrimidine such as pyrimethamine
- salbutamol and formoterol methotrexate
- azathioprine, cyclosporine Interferon gamma 1b
- alemtuzumab, basiliximab, efalizumab, natalizumab
- sunitinib, nilotinib, lapatinib
- mitoxantrone, Hydroxycarbamide, mercaptopurine
- taking of prescription and non-prescription drugs for cognitive enhancement (except cholinesterase inhibitors and memantine at a stable dose for at least 3 months before baseline)
- therapy with anticoagulants except acetylsalicylic acid
- HbA1c in screening more than 10% above the upper limit of normal
- magnesium, sodium, calcium and potassium levels outside the normal range (at screening and baseline)
- existing anemia with Hb <11 (at screening and baseline)
- existing thrombocytopenia; platelet ≤150.000 / ul, leukocytes ≤ 3.000 / ul, neutrophils absolutely ≤ 1.500 / ul (at screening and baseline)
- prothrombin or INR ≥ 1.5 above the laboratory limit of normal; PTT ≥ 1.5 x above the laboratory limit of normal (at screening and baseline)
- clinically relevant renal and / or hepatic impairment at screening and baseline (total bilirubin ≥ 1.5 x above the upper limit of the norm and / or GPT, AST ≥ 4x above the upper limit of the norm and / or creatinine ≥ 1.5x above the upper limit of the norm and / or creatinine clearance <60 ml / min)
- hematuria> 15 RBCs / mL at screening and baseline
- proteinuria at screening and baseline except in asymptomatic urinary tract infections
- participating in other clinical and therapeutic trials within the last 12 weeks
relevant only for dose confirmation:
- subjects with existing contraindications for performing an MRI if no MRI available from the period of 6 months prior to screening
- cardiac pacemaker
- metal objects in the body, which exclude a 1.5 or 3 T MRI
- claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational drug
N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
|
N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the maximum-tolerated dose (MTD) in elderly subjects during dose escalation
Time Frame: 12 months
|
A MTD is defined as the highest dose with no > grade 1 toxicity according to Common Toxicity Criteria (CTC). The dose-limiting toxicity (DLT) is defined as the dose, which leads with a 30% chance of toxicity to CTC Grade 2 or higher and / or leads to corrected QT interval (QTc)≥480ms and/or increase of QTc >= 50ms compared to baseline |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment - Emergent Adverse Events (Safety)
Time Frame: during dose escalation and during 4 weeks treatment with MTD every week
|
The analysis of safety assessments will include the following data collected for each subject: - Adverse Events (AEs) in the context of Drug Exposure (days) |
during dose escalation and during 4 weeks treatment with MTD every week
|
Quantification of Vorinostat concentration in blood - pharmacokinetics
Time Frame: d21 by 4 weeks treatment with MTD
|
Blood and plasma area under the concentration time curve of Vorinostat from time zero to 8 hours postdose. The pharmacokinetic study will investigate the correlation between dose administered and concentration of Vorinostat in blood. |
d21 by 4 weeks treatment with MTD
|
association of alterations in the genome-wide transcriptome profile with the dose administered, toxicity and treatment response - pharmacodynamics
Time Frame: d21 by 4 weeks treatment with MTD
|
The genome-wide transcriptome profile will be determined as a pharmacodynamic surrogate parameter.
Alterations between baseline and after dose administered will be compared.
The pharmacodynamic study will investigate the correlation between dose administered, alterations in the genome-wide transcriptome profile as well as treatment responses (memory performance) and toxicities.
|
d21 by 4 weeks treatment with MTD
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Histone Deacetylase Inhibitors
- Vorinostat
Other Study ID Numbers
- VostatAD01
- 2014-005311-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
-
Karolinska InstitutetCompletedType 2 Diabetes MellitusSweden
-
Karolinska InstitutetCompletedCoronary Artery Disease | Type 2 Diabetes MellitusSweden
-
Imperial College LondonActive, not recruitingFibromyalgiaUnited Kingdom
-
Imperial College LondonRecruiting
-
Johns Hopkins UniversityHeffter Research InstituteCompletedCancer | Anxiety | Depressive SymptomsUnited States
-
Johns Hopkins UniversityCompletedHealthyUnited States
-
Johns Hopkins UniversityPrecision MolecularTerminatedAmyotrophic Lateral SclerosisUnited States
-
Shanghai 10th People's HospitalShanghai Institute of Materia Medica, Chinese Academy of SciencesActive, not recruiting
-
Johns Hopkins UniversityUnited States Department of DefenseNot yet recruiting
-
Arno TherapeuticsCompletedLymphoma | Solid TumorsUnited States, United Kingdom